

# CELLS, TISSUES AND ORGAN SURVEILLANCE SYSTEM (CTOSS), 2022

**CTOSS** monitors adverse events related to transplantation of cells, tissues, and organs in Canada.

**2011** The system started in 2011. Currently, it only covers tissue transplants. The [link](#) contains a detailed methodology of surveillance.

**30%** of the tissues transplanted in Canada are monitored through four participating provinces in CTOSS.

**72,720** tissues were transplanted during 2011-2022.

**10,363** tissues were transplanted in 2022.


**45** transplantation adverse events (TAEs\*) were reported during 2011-2022.

**7** TAEs were reported related to ocular tissues during 2022. 5 TAEs were bacterial infections. 2 TAEs were graft rejections.


The incidence rate was 1.86 TAEs/1,000 grafts.

## NUMBER OF TISSUES TRANSPLANTED BY SITES, CTOSS 2022\*

\*For Alberta, AB Health Services covers Northern Alberta regions.




## TOTAL TISSUES TRANSPLANTED BY TISSUE TYPES, CTOSS 2022



## TISSUES INVOLVING ADVERSE EVENTS (N=45), CTOSS 2011-2022

- OCULAR (30, 67%)
- BONE (11, 24%)
- TENDON (3, 7%)
- HEART VALVE (1, 2%)



**WITH INCREASED NUMBER OF TISSUES TRANSPLANTED IN 2022, THE INCIDENCE RATES OF TAEs IN FOUR SITES REMAIN SIMILAR.**

\*TAE: Any unintended or untoward medical occurrence that may be consequent or related to cells, tissues, or organs that are transplanted. An adverse event may be considered to be an incident or reaction.